FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3100697436> ?p ?o ?g. }

• W3100697436 abstract "<h3>Background</h3> Checkpoint inhibitors are a promising therapy for patients with solid tumors; however, many patients require additional therapies to maximize clinical benefit or overcome resistance.¹ The type-1 cytokine interleukin-21 (IL-21) is a promising candidate for combination and has shown clinical activity in melanoma and renal cell cancer.² IL-21 has also shown improved efficacy when combined with anti-programmed death (PD)-1 antibodies in preclinical models.^{3 4} AMG 256 is a mutated IL-21 cytokine fused to an anti-PD-1 antibody to combine IL-21 pathway stimulation with checkpoint inhibition—a strategy that is designed to prime and extend the activity of cytotoxic and memory T cells and induce anti-tumor immunity. This first-in-human (FIH) study will assess safety, tolerability, and estimated dosing of AMG 256 monotherapy in patients with advanced solid tumors. <h3>Methods</h3> This is a FIH, multicenter, non-randomized, open-label, phase 1 study (NCT04362748) of AMG 256 in patients with advanced solid tumors. The planned sample size is approximately 100 patients in two parts: part 1 will evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and determine the maximum tolerated dose (MTD), part 2 will evaluate the MTD determined in part 1 to further characterize the safety profile and preliminary tumor response. AMG 256 will be delivered by intravenous (IV) infusion. Enrollment criteria include adults with life expectancy of > 3 months, ECOG performance status ≤ 2, histologically or cytologically confirmed metastatic or locally advanced solid tumors not amenable to curative treatment with surgery or radiation, and at least one measurable lesion ≥ 10 mm that has not undergone biopsy within 3 months of screening scan. Exclusion criteria include primary brain tumor, untreated or symptomatic brain metastases, currently receiving treatment in another investigational device or drug study, or less than 28 days since ending treatment on another investigational device or drug study, history of solid organ transplantation or major surgery within 28 days of study day 1, live vaccine therapy within 4 weeks prior to study day 1, and active infection requiring oral or IV therapy. The primary endpoints are incidence of dose-limiting toxicities and adverse events, MTD, and recommended phase 2 dose. Secondary objectives will evaluate PK parameters, preliminary antitumor activity (objective response, duration of response, progression-free survival, disease control rate, duration of stable disease, overall survival), and immunogenicity of AMG 256 via incidence of anti-AMG 256 antibodies. <h3>Results</h3> N/A <h3>Conclusions</h3> N/A <h3>Acknowledgements</h3> • The authors thank the investigators, patients, and study staff who are contributing to this study.• The study was sponsored and funded by Amgen Inc. • Medical writing support was provided by Christopher Nosala (Amgen Inc.). <h3>Trial Registration</h3> NCT04362748 <h3>Ethics Approval</h3> The study was approved by all institutional ethics boards. <h3>References</h3> Kluger HM, Tawbi HA, Ascierto ML, et al. Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce. <i>J Immunother Cancer</i> 2020;8:e000398. Thompson JA, Curti BD, Redman BG, <i>et al</i>. Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma. <i>J Clin Oncol</i> 2008;<b>26</b>:2034–2039. Lewis KE, Selby MJ, Masters G, <i>et al</i>. Interleukin-21 combined with PD-1 or CTLA-4 blockade enhances antitumor immunity in mouse tumor models. <i>Oncoimmunology</i>. 2017;7:e1377873. Shen S, Sckisel G, Sahoo A, <i>et al</i>. Engineered IL-21 cytokine muteins fused to anti-PD-1 antibodies can improve CD8+ T cell function and anti-tumor immunity. <i>Front Immunol</i> 2020;<b>11</b>:832." @default.
• W3100697436 created "2020-11-23" @default.
• W3100697436 creator A5001183616 @default.
• W3100697436 creator A5019301771 @default.
• W3100697436 creator A5049181098 @default.
• W3100697436 creator A5063033621 @default.
• W3100697436 creator A5073605756 @default.
• W3100697436 date "2020-11-01" @default.
• W3100697436 modified "2023-09-27" @default.
• W3100697436 title "417 Design and rationale of a phase 1 study evaluating AMG 256, a novel, targeted, IL-21 receptor agonist and anti-PD-1 antibody, in patients with advanced solid tumors" @default.
• W3100697436 doi "https://doi.org/10.1136/jitc-2020-sitc2020.0417" @default.
• W3100697436 hasPublicationYear "2020" @default.
• W3100697436 type Work @default.
• W3100697436 sameAs 3100697436 @default.
• W3100697436 citedByCount "2" @default.
• W3100697436 countsByYear W31006974362021 @default.
• W3100697436 countsByYear W31006974362023 @default.
• W3100697436 crossrefType "proceedings-article" @default.
• W3100697436 hasAuthorship W3100697436A5001183616 @default.
• W3100697436 hasAuthorship W3100697436A5019301771 @default.
• W3100697436 hasAuthorship W3100697436A5049181098 @default.
• W3100697436 hasAuthorship W3100697436A5063033621 @default.
• W3100697436 hasAuthorship W3100697436A5073605756 @default.
• W3100697436 hasBestOaLocation W31006974362 @default.
• W3100697436 hasConcept C111113717 @default.
• W3100697436 hasConcept C112705442 @default.
• W3100697436 hasConcept C121608353 @default.
• W3100697436 hasConcept C126322002 @default.
• W3100697436 hasConcept C143998085 @default.
• W3100697436 hasConcept C159654299 @default.
• W3100697436 hasConcept C197934379 @default.
• W3100697436 hasConcept C203014093 @default.
• W3100697436 hasConcept C2777288759 @default.
• W3100697436 hasConcept C2777658100 @default.
• W3100697436 hasConcept C2777701055 @default.
• W3100697436 hasConcept C2778375690 @default.
• W3100697436 hasConcept C2778690821 @default.
• W3100697436 hasConcept C2780030458 @default.
• W3100697436 hasConcept C2780850621 @default.
• W3100697436 hasConcept C3875195 @default.
• W3100697436 hasConcept C502942594 @default.
• W3100697436 hasConcept C535046627 @default.
• W3100697436 hasConcept C71924100 @default.
• W3100697436 hasConcept C98274493 @default.
• W3100697436 hasConceptScore W3100697436C111113717 @default.
• W3100697436 hasConceptScore W3100697436C112705442 @default.
• W3100697436 hasConceptScore W3100697436C121608353 @default.
• W3100697436 hasConceptScore W3100697436C126322002 @default.
• W3100697436 hasConceptScore W3100697436C143998085 @default.
• W3100697436 hasConceptScore W3100697436C159654299 @default.
• W3100697436 hasConceptScore W3100697436C197934379 @default.
• W3100697436 hasConceptScore W3100697436C203014093 @default.
• W3100697436 hasConceptScore W3100697436C2777288759 @default.
• W3100697436 hasConceptScore W3100697436C2777658100 @default.
• W3100697436 hasConceptScore W3100697436C2777701055 @default.
• W3100697436 hasConceptScore W3100697436C2778375690 @default.
• W3100697436 hasConceptScore W3100697436C2778690821 @default.
• W3100697436 hasConceptScore W3100697436C2780030458 @default.
• W3100697436 hasConceptScore W3100697436C2780850621 @default.
• W3100697436 hasConceptScore W3100697436C3875195 @default.
• W3100697436 hasConceptScore W3100697436C502942594 @default.
• W3100697436 hasConceptScore W3100697436C535046627 @default.
• W3100697436 hasConceptScore W3100697436C71924100 @default.
• W3100697436 hasConceptScore W3100697436C98274493 @default.
• W3100697436 hasLocation W31006974361 @default.
• W3100697436 hasLocation W31006974362 @default.
• W3100697436 hasOpenAccess W3100697436 @default.
• W3100697436 hasPrimaryLocation W31006974361 @default.
• W3100697436 hasRelatedWork W1736016875 @default.
• W3100697436 hasRelatedWork W1822154343 @default.
• W3100697436 hasRelatedWork W2021831895 @default.
• W3100697436 hasRelatedWork W2028648326 @default.
• W3100697436 hasRelatedWork W2112620969 @default.
• W3100697436 hasRelatedWork W2626992247 @default.
• W3100697436 hasRelatedWork W2899652252 @default.
• W3100697436 hasRelatedWork W2922882148 @default.
• W3100697436 hasRelatedWork W4319063555 @default.
• W3100697436 hasRelatedWork W1962564742 @default.
• W3100697436 isParatext "false" @default.
• W3100697436 isRetracted "false" @default.
• W3100697436 magId "3100697436" @default.
• W3100697436 workType "article" @default.